CR10099A - Inmunoglobulinas dirigidas contra nogo - Google Patents
Inmunoglobulinas dirigidas contra nogoInfo
- Publication number
- CR10099A CR10099A CR10099A CR10099A CR10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A
- Authority
- CR
- Costa Rica
- Prior art keywords
- directed against
- immunoglobulins directed
- against nogo
- nogo
- immunoglobulins
- Prior art date
Links
- 108010077641 Nogo Proteins Proteins 0.000 title abstract 2
- 102100029831 Reticulon-4 Human genes 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0525662.3A GB0525662D0 (en) | 2005-12-16 | 2005-12-16 | Immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10099A true CR10099A (es) | 2008-09-22 |
Family
ID=35736284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10099A CR10099A (es) | 2005-12-16 | 2008-06-20 | Inmunoglobulinas dirigidas contra nogo |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8362208B2 (enExample) |
| EP (2) | EP1960429B1 (enExample) |
| JP (1) | JP5015949B2 (enExample) |
| KR (1) | KR101355118B1 (enExample) |
| CN (1) | CN101374863B (enExample) |
| AR (1) | AR057239A1 (enExample) |
| AU (1) | AU2006325228B2 (enExample) |
| BR (1) | BRPI0619855A2 (enExample) |
| CA (1) | CA2633501C (enExample) |
| CR (1) | CR10099A (enExample) |
| CY (1) | CY1113094T1 (enExample) |
| DK (1) | DK1960429T3 (enExample) |
| EA (1) | EA015536B1 (enExample) |
| ES (1) | ES2389380T3 (enExample) |
| GB (1) | GB0525662D0 (enExample) |
| HR (1) | HRP20120684T1 (enExample) |
| IL (1) | IL192086A0 (enExample) |
| JO (1) | JO2795B1 (enExample) |
| MA (1) | MA30041B1 (enExample) |
| MY (1) | MY149492A (enExample) |
| NO (1) | NO20082699L (enExample) |
| NZ (1) | NZ569143A (enExample) |
| PE (1) | PE20071099A1 (enExample) |
| PL (1) | PL1960429T3 (enExample) |
| PT (1) | PT1960429E (enExample) |
| SI (1) | SI1960429T1 (enExample) |
| TW (1) | TWI378940B (enExample) |
| UA (1) | UA96279C2 (enExample) |
| WO (1) | WO2007068750A2 (enExample) |
| ZA (2) | ZA200805111B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| JP5698534B2 (ja) * | 2007-11-02 | 2015-04-08 | ノバルティス アーゲー | 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用 |
| PE20091965A1 (es) | 2008-05-06 | 2010-01-09 | Glaxo Group Ltd | Encapsulacion de agentes biologicamente activos |
| WO2010004031A2 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| WO2014006105A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| US11013815B2 (en) | 2017-06-14 | 2021-05-25 | Monojul, Llc | High-affinity anti-human folate receptor beta antibodies and methods of use |
| JP7617040B2 (ja) * | 2019-06-13 | 2025-01-17 | プレステージ バイオファーマ リミテッド | Ｃｔｈｒｃ１に特異的な新規抗体及びその使用 |
| PH12022550992A1 (en) | 2019-10-24 | 2023-09-25 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| MX2023015152A (es) | 2021-06-17 | 2024-05-31 | Petmedix Ltd | Anticuerpos anti-cd20 canino. |
| AU2022369106B2 (en) | 2021-10-21 | 2025-10-02 | Zoetis Services Uk Limited | Proteins comprising the extracellular domain of p75ntr |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| JP2025506488A (ja) | 2022-02-09 | 2025-03-11 | ペットメディックス・リミテッド | 治療抗体 |
| CN119768424A (zh) * | 2022-08-22 | 2025-04-04 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
| GB202217993D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
| EP4662226A1 (en) | 2023-02-09 | 2025-12-17 | Zoetis Services UK Limited | Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| SK282722B6 (sk) | 1994-05-27 | 2002-11-06 | Smithkline Beecham S.P.A. | N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| ATE275415T1 (de) | 1995-06-27 | 2004-09-15 | Res Foundation Of Cuny Hunter | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| WO2000005364A1 (en) | 1998-07-22 | 2000-02-03 | Smithkline Beecham Plc | Protein similar to neuroendrocrine-specific protein, and encoding cdna |
| ES2529196T3 (es) | 1998-11-06 | 2015-02-17 | University Of Zurich | Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas |
| FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| DE10338136A1 (de) | 2003-08-15 | 2005-03-24 | European Molecular Biology Laboratory | Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| MY144612A (en) * | 2003-12-22 | 2011-10-14 | Glaxo Group Ltd | Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
| JP4782700B2 (ja) * | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| WO2005097184A2 (en) * | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
-
2005
- 2005-12-16 GB GBGB0525662.3A patent/GB0525662D0/en not_active Ceased
-
2006
- 2006-12-14 UA UAA200807663A patent/UA96279C2/ru unknown
- 2006-12-14 PT PT06830633T patent/PT1960429E/pt unknown
- 2006-12-14 SI SI200631393T patent/SI1960429T1/sl unknown
- 2006-12-14 ES ES06830633T patent/ES2389380T3/es active Active
- 2006-12-14 HR HRP20120684TT patent/HRP20120684T1/hr unknown
- 2006-12-14 EP EP06830633A patent/EP1960429B1/en active Active
- 2006-12-14 EA EA200801343A patent/EA015536B1/ru not_active IP Right Cessation
- 2006-12-14 MY MYPI20082130A patent/MY149492A/en unknown
- 2006-12-14 JP JP2008545009A patent/JP5015949B2/ja not_active Expired - Fee Related
- 2006-12-14 PL PL06830633T patent/PL1960429T3/pl unknown
- 2006-12-14 NZ NZ569143A patent/NZ569143A/en not_active IP Right Cessation
- 2006-12-14 KR KR1020087017348A patent/KR101355118B1/ko not_active Expired - Fee Related
- 2006-12-14 PE PE2006001607A patent/PE20071099A1/es not_active Application Discontinuation
- 2006-12-14 AU AU2006325228A patent/AU2006325228B2/en not_active Ceased
- 2006-12-14 TW TW095146890A patent/TWI378940B/zh not_active IP Right Cessation
- 2006-12-14 AR ARP060105524A patent/AR057239A1/es active IP Right Grant
- 2006-12-14 CN CN2006800529521A patent/CN101374863B/zh not_active Expired - Fee Related
- 2006-12-14 WO PCT/EP2006/069737 patent/WO2007068750A2/en not_active Ceased
- 2006-12-14 US US12/097,279 patent/US8362208B2/en not_active Expired - Fee Related
- 2006-12-14 CA CA2633501A patent/CA2633501C/en not_active Expired - Fee Related
- 2006-12-14 DK DK06830633.1T patent/DK1960429T3/da active
- 2006-12-14 EP EP20100162457 patent/EP2228391A3/en not_active Withdrawn
- 2006-12-14 BR BRPI0619855-4A patent/BRPI0619855A2/pt not_active IP Right Cessation
- 2006-12-24 JO JO2006457A patent/JO2795B1/en active
-
2008
- 2008-06-11 NO NO20082699A patent/NO20082699L/no not_active Application Discontinuation
- 2008-06-11 MA MA31018A patent/MA30041B1/fr unknown
- 2008-06-11 ZA ZA200805111A patent/ZA200805111B/xx unknown
- 2008-06-12 IL IL192086A patent/IL192086A0/en not_active IP Right Cessation
- 2008-06-20 CR CR10099A patent/CR10099A/es unknown
-
2009
- 2009-09-04 ZA ZA200906162A patent/ZA200906162B/en unknown
-
2012
- 2012-09-05 CY CY20121100801T patent/CY1113094T1/el unknown
-
2013
- 2013-01-28 US US13/751,588 patent/US20130287781A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
| AR048912A1 (es) | Inmunoglobulinas anti-nogo | |
| ECSP088804A (es) | Antagonistas de los piridil amida de los canales de calcio de tipo t | |
| BRPI0516483A (pt) | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade | |
| PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| UY29983A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
| EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
| ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
| BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| ECSP066559A (enExample) | ||
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| CY1113310T1 (el) | Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
| CL2004000535A1 (es) | Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino. | |
| AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
| HN2003000104A (es) | Derivados de ciclopenteno | |
| UY29417A1 (es) | Agentes endoparasiticidas | |
| EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
| BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral |